Glass Jacobson Investment Advisors llc Decreases Stake in Johnson & Johnson $JNJ

Key Points

• Glass Jacobson Investment Advisors LLC reduced its stake in Johnson & Johnson by 79.7%, owning 886 shares worth approximately $135,000 at the end of the second quarter.
• Insider Jennifer L. Taubert sold 56,471 shares at an average price of $177.81, resulting in a total transaction value of over $10 million and reflecting a 24.08% decrease in her holdings.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, with a dividend yield of 2.7%, expected to be paid on December 9th to investors of record on November 25th.

Glass Jacobson Investment Advisors llc lessened its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 79.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 886 shares of the company's stock after selling 3,473 shares during the quarter. Glass Jacobson Investment Advisors llc's holdings in Johnson & Johnson were worth $135,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $35,000. Stone House Investment Management LLC bought a new position in Johnson & Johnson during the 1st quarter valued at approximately $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson during the first quarter valued at approximately $52,000. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 1.1%

Johnson & Johnson stock opened at $190.38 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The company has a market capitalization of $458.69 billion, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The business's fifty day simple moving average is $182.26 and its two-hundred day simple moving average is $166.25. The company has a current ratio of 1.07, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is 50.19%.

Analyst Ratings Changes

Several analysts recently weighed in on JNJ shares. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Weiss Ratings raised shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, October 8th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Bank of America raised their price objective on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a "neutral" rating in a report on Wednesday, October 15th. Finally, The Goldman Sachs Group upped their target price on Johnson & Johnson from $186.00 to $212.00 and gave the stock a "buy" rating in a report on Thursday, October 9th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.